Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors
Clinical trial NCT01662804 · COMPLETED
Trial details
- NCT number
- NCT01662804
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2012-08-06
- Primary completion
- 2021-05-25
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.